RIP1 kinase is an oncogenic driver in melanoma

Cancer Research

Volumn 75, Issue 8, 2015, Pages 1736-1748

  Liu, Xiao Ying ^a,b   Lai, Fritz ^a   Yan, Xu Guang ^a   Jiang, Chen Chen ^a   Guo, Su Tang ^a,c   Wang, Chun Yan ^a,c   Croft, Amanda ^a   Tseng, Hsin Yi ^a   Wilmott, James S ^d   Scolyer, Richard A ^d   Jin, Lei ^a   Zhang, Xu Dong ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c Shanxi Cancer Hospital and Institution   (China)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR INTERACTING PROTEIN KINASE 1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CELL ANCHORAGE; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RNA DEGRADATION; UBIQUITINATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL TRANSFORMATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MELANOCYTE; METABOLISM; NUDE MOUSE; ONCOGENE; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SKIN TUMOR;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; NF-KAPPA B; ONCOGENES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84936133277     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2199     Document Type: Article

References (49)

1. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012;132(3 Pt 2):854-63.
2. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-6.
3. Das ThakurM, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance inmelanoma reveals a strategy to forestall drug resistance. Nature 2013;494:251-5.
4. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, et al. MEKindependent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 2011;17:721-30.
5. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007;14:400-10.
6. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008;133:693-703.
7. Christofferson DE, Yuan JY. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 2010;22:263-68.
8. Christofferson DE, Li Y, Hitomi J, Zhou W, Upperman C, Zhu H, et al. A novel role for RIP1 kinase in mediating TNFalpha production. Cell Death Dis 2012;3:e320.
9. Bertrand MJM, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689-700.
10. Imre G, Larisch S, Rajalingam K. Ripoptosome: a novel IAP-regulated cell death-signalling platform. J Mol Cell Biol 2011;3:324-26.
11. Niu J, Shi Y, Iwai K, Wu ZH. LUBAC regulates NF-kappaB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J 2011;30:3741-53.
12. Blackwell K, Zhang L, Workman LM, Ting AT, Iwai K, Habelhah H. Two coordinated mechanisms underlie tumor necrosis factor alpha-induced immediate and delayed IkappaB kinase activation. Mol Cell Biol 2013;33:1901-15.
13. Emmerich CH, Ordureau A, Strickson S, Arthur JS, Pedrioli PG, Komander D, et al. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci U S A 2013;110:15247-52.
14. Yang QH, Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem 2004; 279:16963-70.
15. Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J, et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Diff 2011;18:1376-86.
16. Zobel K, Wang L, Varfolomeev E, Franklin MC, Elliott LO, Wallweber HJ, et al. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006;1:525-33.
17. Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the TNFalpha-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS One 2013;8:e76841.
18. Bellail AC, Olson JJ, Yang X, Chen ZJ, HaoC. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov 2012;2:140-55.
19. Cho Y, McQuade T, Zhang H, Zhang J, Chan FK. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One 2011;6:e23209.
20. Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell 2011; 145:92-103.
21. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011;43:449-63.
22. Wertz IE, Dixit VM. Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol 2010;2:a003350.
23. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, et al. MicroRNA-149-, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci U S A 2011;108:15840-5.
24. Dong L, Jin L, Tseng HY, Wang CY, Wilmott JS, Yosufi B, et al. Oncogenic suppression of PHLPP1 in human melanoma. Oncogene 2014;33: 4756-66.
25. Nguyen T, Zhang XD, Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 2001;7(3 Suppl):966s-73s.
26. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H, et al. Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 2011;30:3716-26.
27. Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, et al. PI(4, 5)P2 5- phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat Commun 2013;4:1508.
28. Lai F, Guo ST, Jin L, Jiang CC, Wang CY, Croft A, et al. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis 2013;4:e655.
29. Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, et al. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death Dis 2013;4:e914.
30. Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, et al. Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell Death Dis 2012;3:e337.
31. Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E, et al. Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death Diff 2010;17:1354-67.
32. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011;43:432-48.
33. McNulty SE, del Rosario R, Cen D, Meyskens FL Jr., Yang S. Comparative expression ofNFkappaB proteins inmelanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res 2004;17:173-80.
34. KarinM. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999;18:6867-74.
35. Yang Y, Xia F, Hermance N, Mabb A, Simonson S, Morrissey S, et al. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NFkappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol 2011;31: 2774-86.
36. Bergenwald C, Westermark G, Sander B. Variable expression of tumor necrosis factor alpha in human malignant melanoma localized by in situ hybridization for mRNA. Cancer Immunol Immun 1997;44: 335-40.
37. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappa B activation and confers a worse prognosis in glioblastoma. Cancer Res 2009;69:2809-16.
38. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP, et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 2008;14:1659-68.
39. Chen W, Wang Q, Bai L, Chen W, Wang X, Tellez CS, et al. RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1alpha-mediated mitochondrial oxidative phosphorylation and glycolysis. Cell DeathDiffer 2014;21:1061-70.
40. Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, et al. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001;166: 5337-45.
41. O'Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol 2007;17:418-24.
42. Tanaka R, Donovan NC, Yu Q, Irie RF, Hoon DS. Tumor necrosis factoralpha and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A. J Invest Dermatol 2014; 134:1470-2.
43. Gray-Schopfer VC, Karasarides M, Hayward R, Marais R. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res 2007;67:122-9.
44. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006;11:397-408.
45. Popa C, NeteaMG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediarymetabolism, and cardiovascular risk. J Lipid Res 2007;48:751-62.
46. Petersen SL, Wang L, Yalcin-Chin A, Li L, PeytonM, Minna J, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smacmimetic- induced apoptosis. Cancer Cell 2007;12:445-56.
47. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-79.
48. Lee TH, Shank J, Cusson N, Kelliher MA. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem 2004;279:33185-91.
49. Vanlangenakker N, Bertrand MJM, Bogaert P, Vandenabeele P, Vanden Berghe T. TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis 2011;2: e230.